US FDA approves Omontys for treatment of anaemia due to CKD in adults patients ... - pharmabiz.com PDF Print
pharmabiz.com
Omontys is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia to be made available to the dialysis patient population in the United States. Omontys (peginesatide) injection is a synthetic, pegylated, peptide-based ESA.
Affymax Wins Approval of Drug for Anemic Kidney Patients Bloomberg
FDA Approves New Anemia Drug New York Times
FDA Clears Affymax and Takeda's Once-Monthly ESA for Anemic CKD Patients on

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.